Clinical Trial Update: A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated atezolizumab plus cobimetinib and vemurafenib versus placebo plus cobimetinib and vemurafenib in previously untreated BRAF V600 mutati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cotellic (cobimetinib)
• Tecentriq (atezolizumab)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2020-11-19